Abbonarsi

The RICH LIFE Project: A cluster randomized pragmatic trial comparing the effectiveness of health system only vs. health system Plus a collaborative/stepped care intervention to reduce hypertension disparities - 16/08/20

Doi : 10.1016/j.ahj.2020.05.001 
Lisa A. Cooper, MD, MPH a, b, c, d, , 1 , Jill A. Marsteller, PhD, MPP ab, c, d, a, Kathryn A. Carson, ScM a, b, c, d, Katherine B. Dietz, MPH a, b, Romsai T. Boonyasai, MD, MPH a, b, d, Carmen Alvarez, PhD, RN, CRNP b, e, Chidinma A. Ibe, PhD a, b, d, Deidra C. Crews, MD a, b, c, Hsin-Chieh Yeh, PhD a, b, c, d, Edgar R. Miller, MD, PhD a, b, c, d, Cheryl R. Dennison-Himmelfarb, PhD, RN a, b, d, e, Lisa H. Lubomski, PhD a, b, d, Tanjala S. Purnell, PhD, MPH a, b, c, d, Felicia Hill-Briggs, PhD a, b, c, d, e, Nae-Yuh Wang, PhD a, b, c, d
for the

RICH LIFE Project Investigators

a Johns Hopkins University School of Medicine, Baltimore, MD, USA 
b Johns Hopkins Center for Health Equity, Johns Hopkins University, Baltimore, MD, USA 
c The Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA 
d Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA 
e John Hopkins University School of Nursing, Baltimore, MD, USA 

Reprint requests: Lisa A. Cooper, MD, MPH, 2024 East Monument Street, Suite 2-500, Baltimore, Maryland 21287.2024 East Monument Street, Suite 2-500BaltimoreMaryland21287

Background

Disparities in the control of hypertension and other cardiovascular disease risk factors are well-documented in the United States, even among patients seen regularly in the healthcare system. Few existing approaches explicitly address disparities in hypertension care and control. This paper describes the RICH LIFE Project (Reducing Inequities in Care of Hypertension: Lifestyle Improvement for Everyone) design.

Methods

RICH LIFE is a two-arm, cluster-randomized trial, comparing the effectiveness of enhanced standard of care, “Standard of Care Plus” (SCP), to a multi-level intervention, “Collaborative Care/Stepped Care” (CC/SC), for improving blood pressure (BP) control and patient activation and reducing disparities in BP control among 1890 adults with uncontrolled hypertension and at least one other cardiovascular disease risk factor treated at 30 primary care practices in Maryland and Pennsylvania. Fifteen practices randomized to the SCP arm receive standardized BP measurement training; race/ethnicity-specific audit and feedback of BP control rates; and quarterly webinars in management practices, quality improvement and disparities reduction. Fifteen practices in the CC/SC arm receive the SCP interventions plus implementation of the collaborative care model with stepped-care components (community health worker referrals and virtual specialist-panel consults). The primary clinical outcome is BP control (<140/90 mm Hg) at 12 months. The primary patient-reported outcome is change from baseline in self-reported patient activation at 12 months.

Discussion

This study will provide knowledge about the feasibility of leveraging existing resources in routine primary care and potential benefits of adding supportive community-facing roles to improve hypertension care and reduce disparities.

Trial Registration

Clinicaltrials.gov NCT02674464

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2020  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 226

P. 94-113 - Agosto 2020 Ritorno al numero
Articolo precedente Articolo precedente
  • Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for evention of cute rspiray dstress syndrome in hospitlized patiets with SARS--2 nfection isease
  • D. H. Frank Gommans, Joris Nas, Sara-Joan Pinto-Sietsma, Yvonne Koop, Regina E. Konst, Frans Mensink, Goaris W.A. Aarts, Lara S.F. Konijnenberg, Kimberley Cortenbach, Dominique V.M. Verhaert, Jos Thannhauser, Jan-Quinten Mol, Maxim J.P. Rooijakkers, Jacqueline L. Vos, Anouke van Rumund, Priya Vart, Robert-Jan Hassing, Jan-Hein Cornel, C. Peter C. de Jager, Michel M. van den Heuvel, Hans G. van der Hoeven, Annelies Verbon, Yigal M. Pinto, Niels van Royen, Roland R.J. van Kimmenade, Event committee, Peter W. de Leeuw, Michiel A. van Agtmael, Paul Bresser, Data Safety Monitoring Board, Wiek H. van Gilst, Anton Vonk-Noordergraaf, Jan G.P. Tijssen, Steering committee, Niels van Royen, C. Peter C. de Jager, Michel M. van den Heuvel, Hans G. van der Hoeven, Annelies Verbon, Yigal M. Pinto, Roland R.J. van Kimmenade
| Articolo seguente Articolo seguente
  • The Second Strategic Reperfusion Early After Myocardial Infarction (STREAM-2) study optimizing pharmacoinvasive reperfusion strategy in older ST-elevation myocardial infarction patients
  • Paul W. Armstrong, Kris Bogaerts, Robert Welsh, Peter R. Sinnaeve, Patrick Goldstein, Alain Pages, Thierry Danays, Frans Van de Werf, on behalf of the STREAM 2 Study Groups (appendix)

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.